Pivotal Phase 3 Clinical Trial Investigates Efficacy of MaaT Pharma’s Most Advanced Microbiome Ecosystem Therapy, MaaT013, as a Third-Line Treatment in Patients with Acute Graft-vs-Host Disease with Gastrointestinal Component -intestinal and resistant to steroids (SR GI-aGvH).
ARES is the first global Phase 3 study for a biotherapy derived from the microbiota in hemato-oncology.
“The initiation of the pivotal Phase 3 trial with MaaT013, our most advanced drug candidate, is a significant milestone for our company and for the global microbiota therapies industry. If ARES proves successful, we believe this study could support approval of the MaaT013 treatment in this severe indication with significant unmet medical need. says Hervé Affagard, co-founder and CEO of MaaT Pharma.
For further details: [email protected]